John B. Wirthlin joined LUMEA in 2015 with more than fifteen years of experience starting and growing innovative life science companies. He has led many companies to success, including AlloCure Inc. and Echelon Biosciences Inc. and has been a valuable asset to LUMEA’s leadership team. Mr. Wirthlin earned an MBA from Westminster College with an emphasis on technology commercialization.
Chief Medical Officer, Co-Founder
Dr. Matthew O. Leavitt co-founded LUMEA after stepping down from his role as a pathologist and laboratory department chair at an Intermountain Healthcare regional hospital. He works in the LUMEA lab to interpret clinical biopsy samples, validate LUMEA technology, and oversee clinical trials. Dr. Leavitt completed his medical training at Dartmouth Medical School and Stanford University Hospitals.
Chief Commercialization Officer
James Thackeray has over 18 years experience working for top biotechnology and diagnostic organizations. He was a 2014 SAMY award winner, awarded by Utah Business Magazine to the top sales and marketing individuals in the state of Utah. Mr. Thackeray earned an MBA with honors at The David Eccles School of Business Executive Program at the University of Utah.
Chief Information Officer
Andy Ivie has over 10 years of experience in software development innovation and leadership. As one of the first LUMEA employees, he built the initial prototype of BiopsyLink and its associated products. He now leads a team of talented software developers who work to refine and expand LUMEA's cutting edge technology with a focus on security and performance.
Chief Technology Officer, Co-Founder
Dr. Mark Evans has over 30 years of experience leading research and development teams in the areas of automation, measurement systems, product development, and business management. He founded the engineering and automation company Direct Controls, Inc. Dr. Evans earned a PhD in Automation and Robotics at the Rensselaer Polytechnic Institute in Troy, New York.
Dr. Sorin Musat specializes in anatomical pathology. He holds a number of patents in the field of high-throughput pathology and introduced the first tissue microarray in routine clinical diagnostics. His research interests include experimental pathology and standardizing histology practices. Dr. Musat earned a PhD in Cell Biology and Histology at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania.
Cory Macy has over 12 years experience at the Controller level for large companies in both Utah and Nevada. He is a former auditor with PricewaterhouseCoopers where he spent several years performing and managing financial audit engagements for SEC registered companies. He has considerable experience in accounting and financial reporting within the technology, hospitality, and real estate industries. Mr. Macy is a graduate of the Woodbury School of Business at Utah Valley University.